A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis

Status Completed

Clinical Trial Summary

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00616434
Study type	Interventional
Source	Biogen
Contact
Status	Completed
Phase	Phase 2
Start date	May 2008
Completion date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00603733` - Canadian Active & Maintenance Modified Pentasa Study	Phase 3
Completed	`NCT01257386` - Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis	Phase 3
Completed	`NCT02748590` - Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)	N/A
Completed	`NCT01745770` - TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)	Phase 3
Completed	`NCT03235752` - Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis	Phase 2
Recruiting	`NCT05739864` - Superdonor FMT in Patients With Ulcerative Colitis	Phase 1/Phase 2